Funding/support:
This work is supported by the National Natural Science Foundation of China (82071730 to X.H.L and 82088102 to H.F.H), CAMS Innovation Fund for Medical Sciences (2019-I2M-5-064 to H.F.H), Open Fund Project of Guangdong Academy of Medical Sciences (YKY-KF202202 to H.F.H), Collaborative Innovation Program of Shanghai Municipal Health Commission (2020CXJQ01 to H.F.H), Clinical Research Plan of SHDC (SHDC2020CR1008A to H.F.H and SHDC12019X17 to X.H.L), Shanghai Clinical Research Center for Gynecological Diseases (22MC1940200 to H.F.H), Shanghai Urogenital System Diseases Research Center (2022ZZ01012 to H.F.H), Shanghai Frontiers Science Research Base of Reproduction and Development and the Clinical Research Plan of IPMCH (IPMCH2022CR1-03 to D.D.W).
Role of the funder/sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.
Patient consent and approval:  The authors have obtained both informed written consent and ethics committee approval for studies on patients and patient records. 
REFERENCES
1. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-31.
2. Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, Makela SM, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet. 2010;375(9726):1609-23.
3. Wanderer JP, Leffert LR, Mhyre JM, Kuklina EV, Callaghan WM, Bateman BT. Epidemiology of obstetric-related ICU admissions in Maryland: 1999-2008*. Crit Care Med. 2013;41(8):1844-52.
4. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. 2010;116(6):1302-9.
5. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. JAMA Netw Open. 2021;4(5):e218401.
6. Li N, An H, Li Z, Ye R, Zhang L, Li H, et al. Preconception blood pressure and risk of gestational hypertension and preeclampsia: a large cohort study in China. Hypertens Res. 2020;43(9):956-62.
7. Coutinho T, Lamai O, Nerenberg K. Hypertensive Disorders of Pregnancy and Cardiovascular Diseases: Current Knowledge and Future Directions. Curr Treat Options Cardiovasc Med. 2018;20(7):56.
8. Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A. All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease. Hypertension. 2017;70(4):798-803.
9. Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017;217(6):685 e1- e5.
10. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402-14.
11. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;326(12):1192-206.
12. Serra B, Mendoza M, Scazzocchio E, Meler E, Nolla M, Sabria E, et al. A new model for screening for early-onset preeclampsia. Am J Obstet Gynecol. 2020;222(6):608 e1- e18.
13. Del Vecchio G, Li Q, Li W, Thamotharan S, Tosevska A, Morselli M, et al. Cell-free DNA Methylation and Transcriptomic Signature Prediction of Pregnancies with Adverse Outcomes. Epigenetics. 2021;16(6):642-61.
14. Wu DD, Gao L, Huang O, Ullah K, Guo MX, Liu Y, et al. Increased Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a Low-Risk Cohort: Evidence From 47 874 Cases. Hypertension. 2020;75(3):772-80.
15. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248.
16. Bello NA, Zhou H, Cheetham TC, Miller E, Getahun DT, Fassett MJ, et al. Prevalence of Hypertension Among Pregnant Women When Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines and Association With Maternal and Fetal Outcomes. JAMA Netw Open. 2021;4(3):e213808.
17. Hu J, Li Y, Zhang B, Zheng T, Li J, Peng Y, et al. Impact of the 2017 ACC/AHA Guideline for High Blood Pressure on Evaluating Gestational Hypertension-Associated Risks for Newborns and Mothers. Circ Res. 2019;125(2):184-94.
18. Sutton EF, Hauspurg A, Caritis SN, Powers RW, Catov JM. Maternal Outcomes Associated With Lower Range Stage 1 Hypertension. Obstet Gynecol. 2018;132(4):843-9.
19. Hauspurg A, Parry S, Mercer BM, Grobman W, Hatfield T, Silver RM, et al. Blood pressure trajectory and category and risk of hypertensive disorders of pregnancy in nulliparous women. Am J Obstet Gynecol. 2019;221(3):277 e1- e8.
20. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat–which of these should we use? Value Health. 2002;5(5):431-6.
21. Slade LJ, Mistry HD, Bone JN, Wilson M, Blackman M, Syeda N, et al. American College of Cardiology and American Heart Association blood pressure categories-a systematic review of the relationship with adverse pregnancy outcomes in the first half of pregnancy. Am J Obstet Gynecol. 2023;228(4):418-29 e34.
22. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol. 2022;226(2S):S1071-S97 e2.
23. Force USPST, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(12):1186-91.
24. Xue RH, Wu DD, Zhou CL, Chen L, Li J, Li ZZ, et al. Association of high maternal triglyceride levels early and late in pregnancy with adverse outcomes: A retrospective cohort study. J Clin Lipidol. 2021;15(1):162-72.
25. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018;72(1):24-43.
26. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10:CD002252.
27. Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, et al. Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension. 2017;70(1):201-8.
28. Zetterstrom K, Lindeberg SN, Haglund B, Hanson U. Maternal complications in women with chronic hypertension: a population-based cohort study. Acta Obstet Gynecol Scand. 2005;84(5):419-24.
29. Bone JN, Magee LA, Singer J, Nathan H, Qureshi RN, Sacoor C, et al. Blood pressure thresholds in pregnancy for identifying maternal and infant risk: a secondary analysis of Community-Level Interventions for Pre-eclampsia (CLIP) trial data. Lancet Glob Health. 2021;9(8):e1119-e28.
30. Hauspurg A, Sutton EF, Catov JM, Caritis SN. Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort. Hypertension. 2018;72(1):202-7.
31. McCarthy FP, Ryan RM, Chappell LC. Prospective biomarkers in preterm preeclampsia: A review. Pregnancy Hypertens. 2018;14:72-8.
32. Petersen EE, Davis NL, Goodman D, Cox S, Mayes N, Johnston E, et al. Vital Signs: Pregnancy-Related Deaths, United States, 2011-2015, and Strategies for Prevention, 13 States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2019;68(18):423-9.
33. He XJ, Dai RX, Hu CL. Maternal prepregnancy overweight and obesity and the risk of preeclampsia: A meta-analysis of cohort studies. Obes Res Clin Pract. 2020;14(1):27-33.
34. Alston MC, Redman LM, Sones JL. An Overview of Obesity, Cholesterol, and Systemic Inflammation in Preeclampsia. Nutrients. 2022;14(10).
35. Spradley FT. Metabolic abnormalities and obesity’s impact on the risk for developing preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2017;312(1):R5-R12.
36. Llurba E, Casals E, Dominguez C, Delgado J, Mercade I, Crispi F, et al. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. Metabolism. 2005;54(11):1504-9.
37. Ziaei S, Bonab KM, Kazemnejad A. Serum lipid levels at 28-32 weeks gestation and hypertensive disorders. Hypertens Pregnancy. 2006;25(1):3-10.
38. Wiznitzer A, Mayer A, Novack V, Sheiner E, Gilutz H, Malhotra A, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol. 2009;201(5):482 e1-8.